Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287487 | 1.00 | TUBB1 (0.41) | TUBB1AAK1 | |
| SCHEMBL12202580 | 1.00 | TUBB1 (0.41) | TUBB1AAK1 | |
| SCHEMBL16861365 | 1.00 | TUBB1 (0.41) | TUBB1AAK1 | |
| SCHEMBL57627 | 0.89 | TUBB1 (0.33) | TUBB1AAK1 | |
| SCHEMBL57433 | 0.81 | NFKB1 (0.32) | TUBB1AAK1 | |
| SCHEMBL10175776 | 0.81 | NFKB1 (0.32) | TUBB1AAK1 | |
| SCHEMBL6670926 | 0.81 | NPSR1 (0.31) | — | |
| SCHEMBL6670924 | 0.81 | NPSR1 (0.31) | — | |
| SCHEMBL90291 | 0.80 | AAK1 (0.31) | AAK1 | |
| SCHEMBL57651 | 0.80 | AAK1 (0.31) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626023-B2 | Compounds for treating tumors | WYETH (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390910-B2 | Compounds for treating tumors | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| WO-2005016958-A2 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050037977-A1 | Compounds for treating tumors | WYETH HOLDINGS CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | RB1, MRPL9, BCOR | TUBB1 588/4885AAK1 3303/4885 |
| US-20050037977-A1 | Compounds for treating tumors | RB1, MRPL9, BCOR | TUBB1 588/4885AAK1 3303/4885 |
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | TUBB1 199/4885AAK1 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.